The goal of the Immune Tolerance Network’s (ITN) type 1 diabetes clinical trials is to find new therapies that can help people maintain some natural insulin production, even after stopping treatment. Two previous ITN trials, T1DAL and AbATE, showed that this was possible in some participants. We now want to know how long these effects can last.
Participating in T1DES
The T1DES study (T1D Extended Study) will follow graduates from T1DAL and AbATE to determine how long they continue to produce insulin. T1DES will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.
This study is observational, meaning there are no study medications or experimental procedures.
Depending on your level of insulin production, T1DES participation may be as short as one return visit or could be up to five years. Participation requires 2 visits per year. These visits will include:
Overall health assessments
Blood and urine collections
Mixed meal tolerance test (MMTTs)* for certain participants
*MMTTs tell doctors how much insulin the body is still making. It involves drinking a special drink that contains a mixture of protein, fat, and carbohydrates. Blood samples are taken at specific time points after drinking.